IPRIPR2022-00796Final Written Decision
Eli Lilly and Companyv.Teva Pharmaceuticals International GmbH et al.
IPR challenge of US 10392434.
Type
IPR
Filed
Apr 11, 2022
Instituted
Oct 14, 2022
Decided
Oct 11, 2023
Patent
Application
15712444
Inventor
Marcelo Bigal et al
Granted
Aug 27, 2019
01
Timeline
3 milestones
2022-04-11Petition filed
2022-10-14Institution
2023-10-11Terminated
02
Parties & counsel
Petitioner
Eli Lilly and Company
Counsel
Feldstein, Market al
Patent Owner
Teva Pharmaceuticals International GmbH et al.
Counsel
Ellison, Eldoraet al
03
Docket
Documents are mirrored from the PTAB e-file system. Filer is as stated on the face of the filing.
SOURCE · USPTO PTAB E2EView on Unified Patents →